KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
[68Ga]Ga-PSMA-11 PET/CT and [18F]Fluorocholine PET/CT in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial. PMID 40437314 · Mol Imaging Biol · 2025-Aug The study is a prospective randomized crossover trial in oncology (human prostate cancer) with original results. However, it is excluded because it does not meet the criteria for a Phase III/IIIb or Phase II/III randomized trial (phase is not specified, but the intervention is diagnostic imaging, not a therapeutic drug) and it lacks a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial. PMID 40437173 · Leukemia · 2025-Aug The record describes a randomized, oncology, human, drug-intervention trial that reports time-to-event efficacy endpoints (DFS, OS). However, the provided metadata does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. The abstract does not mention the phase, and the publication types or MeSH terms do not include a definitive phase designation. Therefore, eligibility cannot be determined without this critical criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. PMID 40425844 · Nat Med · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial. PMID 40419413 · Br J Haematol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort. PMID 40411345 · Genet Med · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term management strategies for pegvaliase use in phenylketonuria: Lessons learned from the phase-3 PRISM open-label extension study. PMID 40411344 · Genet Med · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Presentation and outcomes of second primary malignancies (SPMs) in locally advanced oral cavity squamous carcinoma (LA-OSCC): Secondary analysis of a phase III randomised control trial (NCT00193843). PMID 40409369 · Radiother Oncol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Intrafraction motion stability of open vs. closed facemasks in head and neck radiotherapy: Insights from the OPEN phase III trial. PMID 40409364 · Radiother Oncol · 2025-Aug Study is a phase III randomized trial in head and neck cancer, but it compares radiation immobilization devices (facemasks) and reports on technical motion endpoints (intrafraction deviation, PTV margins), not a drug intervention or time-to-event efficacy outcome.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis. PMID 40404217 · Eur Respir J · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives. PMID 40382526 · Int J Clin Oncol · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial. PMID 40377509 · Cytotherapy · 2025-Aug The study is an oncology, human, Phase IIIb, drug-intervention (tisagenlecleucel) trial with original results, but it is explicitly single-arm (non-randomized) and the reported efficacy endpoint is best response (CR/PR), not a time-to-event outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Antidiabetic and lipid-lowering medication use inversely linked with serum biomarkers of liver fibrosis. PMID 40370077 · Diabetes Obes Metab · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT). PMID 40369354 · Int J Clin Oncol · 2025-Aug 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial. PMID 40365662 · Diabetes Obes Metab · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Baseline Neurocognitive Functioning Among Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana Farber Cancer Institute ALL Consortium Study 16-001. PMID 40361276 · Pediatr Blood Cancer · 2025-Aug The study is an oncology Phase III trial in humans with a drug intervention, but it reports baseline neurocognitive functioning as a secondary/quality-of-life outcome, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analysis). Randomization status is not explicitly established in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Paranasal Sinus and Nasal Cavity Cancers: Systematic Review and Executive Summary of the American Radium Society Appropriate Use Criteria. PMID 40344605 · Head Neck · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level. PMID 40343690 · Rheumatol Ther · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer. PMID 40340174 · Eur Urol Oncol · 2025-Aug The trial is a randomized, prospective study in oncology (bladder cancer) with results, but it compares surveillance methods (marker-based vs. standard cystoscopy) and does not involve a drug-containing intervention. The primary endpoint is diagnostic accuracy (sensitivity) and resource utilization (number of cystoscopies), not a time-to-event efficacy endpoint. Phase is not explicitly stated as III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reappraisal of Biologic Efficacy from Phase 3 Trials in Refractory Chronic Rhinosinusitis and Nasal Polyps. PMID 40340024 · J Allergy Clin Immunol Pract · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials. PMID 40326221 · BJOG · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B. PMID 40320701 · Prostate · 2025-Aug This is a subgroup analysis of a prospective Phase II/III diagnostic trial evaluating the performance of a radiopharmaceutical (18F-piflufolastat) for imaging. It is not a randomized therapeutic trial, does not report time-to-event efficacy outcomes (OS, PFS, etc.), and does not evaluate a systemic drug intervention for treatment efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
QuantiFERON-TB supernatant-based biomarkers predicting active tuberculosis progression. PMID 40320069 · Int J Infect Dis · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial. PMID 40318950 · Eur Urol Oncol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of SDT-001, a dual-task digital device, in managing attention-deficit/hyperactivity disorder symptoms in children and adolescents: a phase 3, randomized, standard treatment-controlled study. PMID 40317565 · Psychiatry Clin Neurosci · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial. PMID 40312180 · Eur Urol Oncol · 2025-Aug The record meets all criteria except explicit confirmation of a definitive phase (Phase III/IIIb or Phase II/III). The study is oncologic, human, randomized, involves a drug intervention, reports original results for a time-to-event primary endpoint, and is a final report. However, the absence of explicit phase information in the provided metadata prevents a definitive eligibility determination, requiring a null is_eligible status.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase. PMID 40302153 · Clin Pharmacol Ther · 2025-Aug The record describes a pharmacokinetic modeling and simulation study using data from a phase III trial. It does not present original results of a randomized trial with a time-to-event efficacy endpoint (OS, PFS, etc.). The focus is on dosing, PK variability, and exposure confirmation, not on clinical efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF. PMID 40300840 · Eur J Heart Fail · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy. PMID 40288917 · Eur Urol Oncol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Custodiol-N versus Custodiol: Results from a prospective noninferiority randomized single blind, multicenter phase 3 trial in patients undergoing heart transplantation. PMID 40280454 · J Heart Lung Transplant · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. PMID 40280279 · Am J Ophthalmol · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Medical and Nutritional Outcomes Are Similar Among Autologous Transplant Patients on Enteral Nutrition When Compared to Parenteral Nutrition. A Randomized Pilot Study. PMID 40273948 · Eur J Haematol · 2025-Aug The study is a randomized, human oncology trial reporting a time-to-event endpoint (OS). However, it is explicitly a pilot study (likely Phase II or earlier), not a Phase III/IIIb or Phase II/III trial, and the intervention is non-drug (nutritional support). Therefore, it does not meet the core eligibility criteria for inclusion in this digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. PMID 40258573 · J Thorac Oncol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SUPE_R): A Randomized Controlled Trial. PMID 40258572 · J Thorac Oncol · 2025-Aug The record is a randomized, controlled, oncology trial in humans with time-to-event endpoints (TTR, OS) and reports primary results. However, it does not include a drug-containing intervention; the interventions are surveillance methods ([18F]FDG PET/CT vs. ceCT). Therefore, it fails the mandatory drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes in the Phase III OASIS-HAE Study of Donidalorsen for Hereditary Angioedema. PMID 40251904 · Allergy · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. PMID 40222820 · Eur J Heart Fail · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial. PMID 40210087 · Ann Oncol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of epicutaneous immunotherapy in children with peanut allergy with atopic comorbidities. PMID 40204253 · Ann Allergy Asthma Immunol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical Trial Protocol for ACCURATE: A CCafU-UroCCR Randomized Trial: Three-dimensional Image-guided Robot-assisted Partial Nephrectomy for Renal Complex Tumor (UroCCR 99). PMID 40199643 · Eur Urol Oncol · 2025-Aug 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Nodal status in major salivary gland cancer: External validation of a novel N- classification. PMID 40194336 · Eur J Surg Oncol · 2025-Aug This is an observational, external validation study of a novel nodal classification system for salivary gland cancer. It is not a randomized controlled trial, does not involve a drug intervention, and is not a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical trials of prevention of acquired epilepsy: New proof-of-concept approach to restart trials. PMID 40184261 · Epilepsia · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial. PMID 40120597 · Lancet Infect Dis · 2025-Aug The study is a Phase III randomized trial of an oncology drug (HPV vaccine) with primary results, but its primary endpoint is immunogenicity (non-inferiority of geometric mean antibody concentrations), not a time-to-event efficacy endpoint like overall survival or progression-free survival. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study. PMID 40113101 · Gastroenterology · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Efficacy of Texture and Color Enhancement Imaging Observation in the Detection of Colorectal Lesions: A Multicenter, Randomized Controlled Trial (deTXIon Study). PMID 40113100 · Gastroenterology · 2025-Aug The study is a randomized, human, oncology-related trial with original results, but it fails on two key eligibility criteria: it is not a drug intervention trial and does not use a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetics and Exposure-Response Analyses of Sarilumab in Patients with Polymyalgia Rheumatica. PMID 40105153 · J Clin Pharmacol · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial. PMID 40087058 · Clin Lymphoma Myeloma Leuk · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence-TIMI 73b trial. PMID 40081744 · Am Heart J · 2025-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. PMID 40064331 · Am Heart J · 2025-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Endoscopic En Bloc vs Piecemeal Resection of Large Colonic Adenomas: Carbon Footprint Post Hoc Analysis of a Randomized Trial. PMID 40049342 · Clin Gastroenterol Hepatol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents With Moderate-to-Severe Atopic Dermatitis. PMID 40028832 · Allergy · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Macular Atrophy-Related Observations in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial. PMID 40015680 · Ophthalmol Retina · 2025-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -